Parkinsons Disease Treatment Market Forecast to 2027 - Covid-19 Impact and Global Analysis - by Drug Class (Carbidopa/Levodopa, Dopamine Receptor Agonists, Mao Inhibitors, Comt Inhibitors, Anticholinergics, Other Drugs); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography
Report Code: TIPRE00003657 No. of Pages: 150 Category: Pharmaceuticals Status: Upcoming
MARKET INTRODUCTION
Parkinsons disease is one of the progressive nervous system disorder that affects the movement of individuals. The symptoms of Parkinsons starts gradually with a barely noticeable tremors in one hand. The further symptoms of the disease usually leads to stiffness, rigid muscles, impaired posture and balance, loss of automatic movement, and slowing of movement. Parkinsons disease cannot be completely cured, however, the medications helps to improve the symptoms of the disease.
MARKET DYNAMICS
The Parkinsons disease treatment market is anticipated to grow in the forecast, owing to the factors such as increasing geriatric population, government funding for Parkinsons disease treatment research and new product launches. In addition, initiatives undertaken by various government and non-government organizations as well as a promising pipeline of the disease medications is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Parkinsons Disease Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Parkinsons disease treatment market with detailed market segmentation by drug class, distribution channel and geography. The global Parkinsons disease treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Parkinsons disease treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Parkinsons disease treatment market is segmented on the basis of drug class, distribution channel and geography. Based on type, the market is segmented as carbidopa/levodopa, dopamine receptor agonists, Mao inhibitors, comt inhibitors, anticholinergic and other drugs. On the basis of distribution channel, the global Parkinsons disease treatment market is segmented into, hospital pharmacies, retail pharmacies, and online pharmacies. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Parkinsons disease treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Parkinsons disease treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Parkinsons disease treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Parkinsons disease treatment market in these regions.
MARKET PLAYERS
The reports cover key developments in the Parkinsons disease treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Parkinsons disease treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for Parkinsons disease treatment market in the global market. Below mentioned is the list of few companies engaged in the Parkinsons disease treatment market.
The report also includes the profiles of key Parkinsons disease treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Parkinsons disease is one of the progressive nervous system disorder that affects the movement of individuals. The symptoms of Parkinsons starts gradually with a barely noticeable tremors in one hand. The further symptoms of the disease usually leads to stiffness, rigid muscles, impaired posture and balance, loss of automatic movement, and slowing of movement. Parkinsons disease cannot be completely cured, however, the medications helps to improve the symptoms of the disease.
MARKET DYNAMICS
The Parkinsons disease treatment market is anticipated to grow in the forecast, owing to the factors such as increasing geriatric population, government funding for Parkinsons disease treatment research and new product launches. In addition, initiatives undertaken by various government and non-government organizations as well as a promising pipeline of the disease medications is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Global Parkinsons Disease Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Parkinsons disease treatment market with detailed market segmentation by drug class, distribution channel and geography. The global Parkinsons disease treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Parkinsons disease treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Parkinsons disease treatment market is segmented on the basis of drug class, distribution channel and geography. Based on type, the market is segmented as carbidopa/levodopa, dopamine receptor agonists, Mao inhibitors, comt inhibitors, anticholinergic and other drugs. On the basis of distribution channel, the global Parkinsons disease treatment market is segmented into, hospital pharmacies, retail pharmacies, and online pharmacies. REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Parkinsons disease treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Parkinsons disease treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Parkinsons disease treatment market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Parkinsons disease treatment market in these regions.
MARKET PLAYERS
The reports cover key developments in the Parkinsons disease treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Parkinsons disease treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for Parkinsons disease treatment market in the global market. Below mentioned is the list of few companies engaged in the Parkinsons disease treatment market.
The report also includes the profiles of key Parkinsons disease treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- GlaxoSmithKline Plc
- Merck KGaA
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim GmbH
- Bausch Health
- H. Lundbeck A/S
- Sun Pharmaceutical Industries Ltd
- AbbVie Inc.
- Impax Laboratories, LLC
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Parkinsons Disease Treatment Market - By Drug Class
1.3.2 Parkinsons Disease Treatment Market - By Distribution Channel
1.3.3 Parkinsons Disease Treatment Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. PARKINSONS DISEASE TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PARKINSONS DISEASE TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. PARKINSONS DISEASE TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. PARKINSONS DISEASE TREATMENT - GLOBAL MARKET OVERVIEW
6.2. PARKINSONS DISEASE TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PARKINSONS DISEASE TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. CARBIDOPA/LEVODOPA
7.3.1. Overview
7.3.2. Carbidopa/Levodopa Market Forecast and Analysis
7.4. DOPAMINE RECEPTOR AGONISTS
7.4.1. Overview
7.4.2. Dopamine Receptor Agonists Market Forecast and Analysis
7.5. MAO INHIBITORS
7.5.1. Overview
7.5.2. Mao Inhibitors Market Forecast and Analysis
7.6. COMT INHIBITORS
7.6.1. Overview
7.6.2. Comt Inhibitors Market Forecast and Analysis
7.7. ANTICHOLINERGICS
7.7.1. Overview
7.7.2. Anticholinergics Market Forecast and Analysis
7.8. OTHER DRUGS
7.8.1. Overview
7.8.2. Other Drugs Market Forecast and Analysis
8. PARKINSONS DISEASE TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. PARKINSONS DISEASE TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Parkinsons Disease Treatment Market Overview
9.1.2 North America Parkinsons Disease Treatment Market Forecasts and Analysis
9.1.3 North America Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.1.4 North America Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Parkinsons Disease Treatment Market
9.1.5.1.1 United States Parkinsons Disease Treatment Market by Drug Class
9.1.5.1.2 United States Parkinsons Disease Treatment Market by Distribution Channel
9.1.5.2 Canada Parkinsons Disease Treatment Market
9.1.5.2.1 Canada Parkinsons Disease Treatment Market by Drug Class
9.1.5.2.2 Canada Parkinsons Disease Treatment Market by Distribution Channel
9.1.5.3 Mexico Parkinsons Disease Treatment Market
9.1.5.3.1 Mexico Parkinsons Disease Treatment Market by Drug Class
9.1.5.3.2 Mexico Parkinsons Disease Treatment Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Parkinsons Disease Treatment Market Overview
9.2.2 Europe Parkinsons Disease Treatment Market Forecasts and Analysis
9.2.3 Europe Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Parkinsons Disease Treatment Market
9.2.5.1.1 Germany Parkinsons Disease Treatment Market by Drug Class
9.2.5.1.2 Germany Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.2 France Parkinsons Disease Treatment Market
9.2.5.2.1 France Parkinsons Disease Treatment Market by Drug Class
9.2.5.2.2 France Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.3 Italy Parkinsons Disease Treatment Market
9.2.5.3.1 Italy Parkinsons Disease Treatment Market by Drug Class
9.2.5.3.2 Italy Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.4 Spain Parkinsons Disease Treatment Market
9.2.5.4.1 Spain Parkinsons Disease Treatment Market by Drug Class
9.2.5.4.2 Spain Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.5 United Kingdom Parkinsons Disease Treatment Market
9.2.5.5.1 United Kingdom Parkinsons Disease Treatment Market by Drug Class
9.2.5.5.2 United Kingdom Parkinsons Disease Treatment Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Parkinsons Disease Treatment Market Overview
9.3.2 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Parkinsons Disease Treatment Market
9.3.5.1.1 Australia Parkinsons Disease Treatment Market by Drug Class
9.3.5.1.2 Australia Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.2 China Parkinsons Disease Treatment Market
9.3.5.2.1 China Parkinsons Disease Treatment Market by Drug Class
9.3.5.2.2 China Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.3 India Parkinsons Disease Treatment Market
9.3.5.3.1 India Parkinsons Disease Treatment Market by Drug Class
9.3.5.3.2 India Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.4 Japan Parkinsons Disease Treatment Market
9.3.5.4.1 Japan Parkinsons Disease Treatment Market by Drug Class
9.3.5.4.2 Japan Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.5 South Korea Parkinsons Disease Treatment Market
9.3.5.5.1 South Korea Parkinsons Disease Treatment Market by Drug Class
9.3.5.5.2 South Korea Parkinsons Disease Treatment Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Parkinsons Disease Treatment Market Overview
9.4.2 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Parkinsons Disease Treatment Market
9.4.5.1.1 South Africa Parkinsons Disease Treatment Market by Drug Class
9.4.5.1.2 South Africa Parkinsons Disease Treatment Market by Distribution Channel
9.4.5.2 Saudi Arabia Parkinsons Disease Treatment Market
9.4.5.2.1 Saudi Arabia Parkinsons Disease Treatment Market by Drug Class
9.4.5.2.2 Saudi Arabia Parkinsons Disease Treatment Market by Distribution Channel
9.4.5.3 U.A.E Parkinsons Disease Treatment Market
9.4.5.3.1 U.A.E Parkinsons Disease Treatment Market by Drug Class
9.4.5.3.2 U.A.E Parkinsons Disease Treatment Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Parkinsons Disease Treatment Market Overview
9.5.2 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis
9.5.3 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Parkinsons Disease Treatment Market
9.5.5.1.1 Brazil Parkinsons Disease Treatment Market by Drug Class
9.5.5.1.2 Brazil Parkinsons Disease Treatment Market by Distribution Channel
9.5.5.2 Argentina Parkinsons Disease Treatment Market
9.5.5.2.1 Argentina Parkinsons Disease Treatment Market by Drug Class
9.5.5.2.2 Argentina Parkinsons Disease Treatment Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. PARKINSONS DISEASE TREATMENT MARKET, KEY COMPANY PROFILES
11.1. GLAXOSMITHKLINE PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. MERCK KGAA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BOEHRINGER INGELHEIM GMBH
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. BAUSCH HEALTH
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. H. LUNDBECK A/S
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SUN PHARMACEUTICAL INDUSTRIES LTD
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ABBVIE INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. IMPAX LABORATORIES, LLC
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Parkinsons Disease Treatment Market - By Drug Class
1.3.2 Parkinsons Disease Treatment Market - By Distribution Channel
1.3.3 Parkinsons Disease Treatment Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. PARKINSONS DISEASE TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PARKINSONS DISEASE TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. PARKINSONS DISEASE TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. PARKINSONS DISEASE TREATMENT - GLOBAL MARKET OVERVIEW
6.2. PARKINSONS DISEASE TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PARKINSONS DISEASE TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. CARBIDOPA/LEVODOPA
7.3.1. Overview
7.3.2. Carbidopa/Levodopa Market Forecast and Analysis
7.4. DOPAMINE RECEPTOR AGONISTS
7.4.1. Overview
7.4.2. Dopamine Receptor Agonists Market Forecast and Analysis
7.5. MAO INHIBITORS
7.5.1. Overview
7.5.2. Mao Inhibitors Market Forecast and Analysis
7.6. COMT INHIBITORS
7.6.1. Overview
7.6.2. Comt Inhibitors Market Forecast and Analysis
7.7. ANTICHOLINERGICS
7.7.1. Overview
7.7.2. Anticholinergics Market Forecast and Analysis
7.8. OTHER DRUGS
7.8.1. Overview
7.8.2. Other Drugs Market Forecast and Analysis
8. PARKINSONS DISEASE TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL PHARMACIES
8.3.1. Overview
8.3.2. Hospital Pharmacies Market Forecast and Analysis
8.4. RETAIL PHARMACIES
8.4.1. Overview
8.4.2. Retail Pharmacies Market Forecast and Analysis
8.5. ONLINE PHARMACIES
8.5.1. Overview
8.5.2. Online Pharmacies Market Forecast and Analysis
9. PARKINSONS DISEASE TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Parkinsons Disease Treatment Market Overview
9.1.2 North America Parkinsons Disease Treatment Market Forecasts and Analysis
9.1.3 North America Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.1.4 North America Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Parkinsons Disease Treatment Market
9.1.5.1.1 United States Parkinsons Disease Treatment Market by Drug Class
9.1.5.1.2 United States Parkinsons Disease Treatment Market by Distribution Channel
9.1.5.2 Canada Parkinsons Disease Treatment Market
9.1.5.2.1 Canada Parkinsons Disease Treatment Market by Drug Class
9.1.5.2.2 Canada Parkinsons Disease Treatment Market by Distribution Channel
9.1.5.3 Mexico Parkinsons Disease Treatment Market
9.1.5.3.1 Mexico Parkinsons Disease Treatment Market by Drug Class
9.1.5.3.2 Mexico Parkinsons Disease Treatment Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Parkinsons Disease Treatment Market Overview
9.2.2 Europe Parkinsons Disease Treatment Market Forecasts and Analysis
9.2.3 Europe Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Parkinsons Disease Treatment Market
9.2.5.1.1 Germany Parkinsons Disease Treatment Market by Drug Class
9.2.5.1.2 Germany Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.2 France Parkinsons Disease Treatment Market
9.2.5.2.1 France Parkinsons Disease Treatment Market by Drug Class
9.2.5.2.2 France Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.3 Italy Parkinsons Disease Treatment Market
9.2.5.3.1 Italy Parkinsons Disease Treatment Market by Drug Class
9.2.5.3.2 Italy Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.4 Spain Parkinsons Disease Treatment Market
9.2.5.4.1 Spain Parkinsons Disease Treatment Market by Drug Class
9.2.5.4.2 Spain Parkinsons Disease Treatment Market by Distribution Channel
9.2.5.5 United Kingdom Parkinsons Disease Treatment Market
9.2.5.5.1 United Kingdom Parkinsons Disease Treatment Market by Drug Class
9.2.5.5.2 United Kingdom Parkinsons Disease Treatment Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Parkinsons Disease Treatment Market Overview
9.3.2 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Parkinsons Disease Treatment Market
9.3.5.1.1 Australia Parkinsons Disease Treatment Market by Drug Class
9.3.5.1.2 Australia Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.2 China Parkinsons Disease Treatment Market
9.3.5.2.1 China Parkinsons Disease Treatment Market by Drug Class
9.3.5.2.2 China Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.3 India Parkinsons Disease Treatment Market
9.3.5.3.1 India Parkinsons Disease Treatment Market by Drug Class
9.3.5.3.2 India Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.4 Japan Parkinsons Disease Treatment Market
9.3.5.4.1 Japan Parkinsons Disease Treatment Market by Drug Class
9.3.5.4.2 Japan Parkinsons Disease Treatment Market by Distribution Channel
9.3.5.5 South Korea Parkinsons Disease Treatment Market
9.3.5.5.1 South Korea Parkinsons Disease Treatment Market by Drug Class
9.3.5.5.2 South Korea Parkinsons Disease Treatment Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Parkinsons Disease Treatment Market Overview
9.4.2 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Parkinsons Disease Treatment Market
9.4.5.1.1 South Africa Parkinsons Disease Treatment Market by Drug Class
9.4.5.1.2 South Africa Parkinsons Disease Treatment Market by Distribution Channel
9.4.5.2 Saudi Arabia Parkinsons Disease Treatment Market
9.4.5.2.1 Saudi Arabia Parkinsons Disease Treatment Market by Drug Class
9.4.5.2.2 Saudi Arabia Parkinsons Disease Treatment Market by Distribution Channel
9.4.5.3 U.A.E Parkinsons Disease Treatment Market
9.4.5.3.1 U.A.E Parkinsons Disease Treatment Market by Drug Class
9.4.5.3.2 U.A.E Parkinsons Disease Treatment Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Parkinsons Disease Treatment Market Overview
9.5.2 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis
9.5.3 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Parkinsons Disease Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Parkinsons Disease Treatment Market
9.5.5.1.1 Brazil Parkinsons Disease Treatment Market by Drug Class
9.5.5.1.2 Brazil Parkinsons Disease Treatment Market by Distribution Channel
9.5.5.2 Argentina Parkinsons Disease Treatment Market
9.5.5.2.1 Argentina Parkinsons Disease Treatment Market by Drug Class
9.5.5.2.2 Argentina Parkinsons Disease Treatment Market by Distribution Channel
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. PARKINSONS DISEASE TREATMENT MARKET, KEY COMPANY PROFILES
11.1. GLAXOSMITHKLINE PLC
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. MERCK KGAA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BOEHRINGER INGELHEIM GMBH
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. BAUSCH HEALTH
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. H. LUNDBECK A/S
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. SUN PHARMACEUTICAL INDUSTRIES LTD
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. ABBVIE INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. IMPAX LABORATORIES, LLC
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. GlaxoSmithKline Plc
2. Merck KGaA
3. Novartis AG
4. Teva Pharmaceutical Industries Ltd.
5. Boehringer Ingelheim GmbH
6. Bausch Health
7. H. Lundbeck A/S
8. Sun Pharmaceutical Industries Ltd
9. AbbVie Inc.
10. Impax Laboratories, LLC
1. GlaxoSmithKline Plc
2. Merck KGaA
3. Novartis AG
4. Teva Pharmaceutical Industries Ltd.
5. Boehringer Ingelheim GmbH
6. Bausch Health
7. H. Lundbeck A/S
8. Sun Pharmaceutical Industries Ltd
9. AbbVie Inc.
10. Impax Laboratories, LLC